5-o-methyl-myo-inositol profile

1D-5-O-methyl-myo-inositol : A member of the class of methyl myo-inositols that is cyclohexane-1,2,3,4,5-pentol substituted by a methoxy group at position 6 (the 1R,2S,3r,4R,5S,6r-stereoisomer). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	439990
CHEMBL ID	460057
CHEBI ID	179104
CHEBI ID	15975
SCHEMBL ID	1888646
SCHEMBL ID	7155914
SCHEMBL ID	1059036
MeSH ID	M0574056

Synonym
(1s,2r,4s,5r)-6-methoxycyclohexane-1,2,3,4,5-pentol
CHEBI:179104
(1r,2s,3r,4r,5s,6r)-6-methoxycyclohexane-1,2,3,4,5-pentol
CHEBI:15975
o-methyl-scyllo-inositol
C03365
523-92-2
1d-5-o-methyl-myo-inositol
C05163
sequoyitol
1-o-methyl-scyllo-inositol
5-o-methyl-myo-inositol ,
6A797581-AC95-4A84-9F74-C05E5465011A
BMSE000740
(1r,2s,4r,5s)-6-methoxycyclohexane-1,2,3,4,5-pentol
CHEMBL460057
AKOS006272498
SCHEMBL1888646
SCHEMBL7155914
S9343
myo-inositol, 5-o-methyl-
einecs 208-352-9
SCHEMBL1059036
AC-32615
2-o-methyl-myo-inositol
(1r,2s,3r,4r,5s,6r)-6-methoxycyclohexane-1,2,3,4,5-pentaol
(+)-3-o-methyl-d-chiro-inositol
HY-N2421
Q27098326
CCG-266528
CS-0022628
MS-23046
(1r,2s,4r,5s)-6-methoxycyclohexane-1,2,3,4,5-pentaol
DTXSID801313753
7600-53-5
E80607

Class	Description
cyclohexanols	An alcohol in which one or more hydroxy groups are attached to a cyclohexane skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
pinitol biosynthesis II	0	16

Assay ID	Title	Year	Journal	Article
AID361505	Effect on amyloid beta 42 aggregation assessed as inhibition of fiber formation at 5 mM	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Synthesis of scyllo-inositol derivatives and their effects on amyloid beta peptide aggregation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (11.11)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (11.11)	29.6817
2010's	7 (77.78)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	9 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
inositol Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.. inositol : Any cyclohexane-1,2,3,4,5,6-hexol.. 1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.. muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.	3.64	9	cyclitol; hexol
1,2-dihydrostilbene 1,2-dihydrostilbene: intermdiate in biosynthesis of dihydrophenanthrenes from phenylalanine. 1,2-dihydrostilbene : A diphenylethane that is the 1,2-dihydro derivative of stilbene.	2.08	1	diphenylethane
oleanolic acid [no description available]	2.08	1	hydroxy monocarboxylic acid; pentacyclic triterpenoid	plant metabolite
malondialdehyde Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.	2.5	2	dialdehyde	biomarker
beta-amyrin beta-amyrin: alpha-amyrin is also available; a 5 ring triterpene derived from oleanane that differs from alpha-amyrin in having the 29-carbon at the 20 position; RN given refers to (3 beta)-isomer. beta-amyrin : A pentacyclic triterpenoid that is oleanane substituted at the 3beta-position by a hydroxy group and containing a double bond between positions 12 and 13. It is one of the most commonly occurring triterpenoids in higher plants.	2.08	1	pentacyclic triterpenoid; secondary alcohol	Aspergillus metabolite; plant metabolite
methylinositol methylinositol: from Ebenus haussknechtii; structure in first source. pinitol : A cyclitol ether formed by etherification of the 3-hydroxy group of chiro-inositol. It is plant metabolite isolated from the leaves of Sutherlandia frutescens.. 1D-4-O-methyl-myo-inositol : A member of the class of methyl myo-inositols that is cyclohexane-1,2,3,4,5-pentol substituted by a methoxy group at position 6 (the 1R,2S,3S,4S,5S,6S-isomer).. D-pinitol : The D-enantiomer of pinitol.	1.94	1
5-deoxyinositol [no description available]	2.04	1
glycosides [no description available]	2.08	1
stilbenes Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.	2.08	1	stilbene
menisdaurin menisdaurin: structure in first source	2.08	1
oxepins Oxepins: Compounds based on a 7-membered heterocyclic ring including an oxygen. They can be considered a medium ring ether. A natural source is the MONTANOA plant genus. Some dibenzo-dioxepins, called depsidones, are found in GARCINIA plants.	2.08	1

Condition	Relationship Strength	Studies
Acute Confusional Senile Dementia [description not available]	2.04	1
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	2.04	1
Alloxan Diabetes [description not available]	3	4
Liver Dysfunction [description not available]	2.08	1
Liver Diseases Pathological processes of the LIVER.	2.08	1
Diabetic Glomerulosclerosis [description not available]	2.1	1
Diabetic Nephropathies KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.	2.1	1
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	2.1	1
Diabetes Mellitus, Adult-Onset [description not available]	2.1	1
Insulin Sensitivity [description not available]	2.49	2
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	2.1	1
Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.	2.49	2
Impaired Glucose Tolerance [description not available]	2.07	1
Hyperglycemia, Postprandial Abnormally high BLOOD GLUCOSE level after a meal.	2.07	1
Hyperglycemia Abnormally high BLOOD GLUCOSE level.	2.07	1
Glucose Intolerance A pathological state in which BLOOD GLUCOSE level is less than approximately 140 mg/100 ml of PLASMA at fasting, and above approximately 200 mg/100 ml plasma at 30-, 60-, or 90-minute during a GLUCOSE TOLERANCE TEST. This condition is seen frequently in DIABETES MELLITUS, but also occurs with other diseases and MALNUTRITION.	2.07	1

5-o-methyl-myo-inositol

Description

Cross-References

Synonyms (36)

Drug Classes (1)

Pathways (1)

Bioassays (1)

Research

Studies (9)

Market Indicators

Research Demand Index: 13.06

Study Types